CN113693131A - Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people - Google Patents
Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people Download PDFInfo
- Publication number
- CN113693131A CN113693131A CN202110954228.4A CN202110954228A CN113693131A CN 113693131 A CN113693131 A CN 113693131A CN 202110954228 A CN202110954228 A CN 202110954228A CN 113693131 A CN113693131 A CN 113693131A
- Authority
- CN
- China
- Prior art keywords
- parts
- linoleic acid
- conjugated linoleic
- trans
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 65
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 58
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 38
- 239000011669 selenium Substances 0.000 title claims abstract description 38
- 239000006041 probiotic Substances 0.000 title claims abstract description 33
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 33
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 33
- 239000011575 calcium Substances 0.000 title claims abstract description 30
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 30
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 105
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 93
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 88
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 26
- 239000011707 mineral Substances 0.000 claims abstract description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 23
- 235000013336 milk Nutrition 0.000 claims abstract description 16
- 239000008267 milk Substances 0.000 claims abstract description 16
- 210000004080 milk Anatomy 0.000 claims abstract description 16
- 229930091371 Fructose Natural products 0.000 claims abstract description 14
- 239000005715 Fructose Substances 0.000 claims abstract description 14
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 12
- 235000020185 raw untreated milk Nutrition 0.000 claims abstract description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 12
- 239000008158 vegetable oil Substances 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 12
- 229930003231 vitamin Natural products 0.000 claims abstract description 12
- 235000013343 vitamin Nutrition 0.000 claims abstract description 12
- 239000011782 vitamin Substances 0.000 claims abstract description 12
- 102000008186 Collagen Human genes 0.000 claims abstract description 11
- 108010035532 Collagen Proteins 0.000 claims abstract description 11
- 229920001436 collagen Polymers 0.000 claims abstract description 11
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 9
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 9
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 9
- 241000283690 Bos taurus Species 0.000 claims abstract description 9
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 9
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 9
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 9
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 9
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 9
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 9
- -1 phytosterol ester Chemical class 0.000 claims abstract description 9
- 229940075999 phytosterol ester Drugs 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 239000005862 Whey Substances 0.000 claims abstract description 6
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 6
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 6
- 235000012907 honey Nutrition 0.000 claims abstract description 6
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 6
- 235000010755 mineral Nutrition 0.000 claims description 23
- IOCYQQQCJYMWDT-UHFFFAOYSA-N (3-ethyl-2-methoxyquinolin-6-yl)-(4-methoxycyclohexyl)methanone Chemical compound C=1C=C2N=C(OC)C(CC)=CC2=CC=1C(=O)C1CCC(OC)CC1 IOCYQQQCJYMWDT-UHFFFAOYSA-N 0.000 claims description 20
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 18
- 239000008101 lactose Substances 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- 235000012424 soybean oil Nutrition 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 10
- 241001608472 Bifidobacterium longum Species 0.000 claims description 7
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 7
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 7
- 239000002211 L-ascorbic acid Substances 0.000 claims description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 7
- 239000011790 ferrous sulphate Substances 0.000 claims description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 7
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 7
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 7
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 7
- 229960000342 retinol acetate Drugs 0.000 claims description 7
- 235000019173 retinyl acetate Nutrition 0.000 claims description 7
- 239000011770 retinyl acetate Substances 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- 235000005282 vitamin D3 Nutrition 0.000 claims description 7
- 239000011647 vitamin D3 Substances 0.000 claims description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 229940021056 vitamin d3 Drugs 0.000 claims description 7
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 7
- 229960001763 zinc sulfate Drugs 0.000 claims description 7
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 229920001202 Inulin Polymers 0.000 claims description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 6
- 229940029339 inulin Drugs 0.000 claims description 6
- GKJZMAHZJGSBKD-NMMTYZSQSA-N (10E,12Z)-octadecadienoic acid Chemical compound CCCCC\C=C/C=C/CCCCCCCCC(O)=O GKJZMAHZJGSBKD-NMMTYZSQSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 239000000905 isomalt Substances 0.000 claims description 5
- 235000010439 isomalt Nutrition 0.000 claims description 5
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 5
- 229960001375 lactose Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- 229960001781 ferrous sulfate Drugs 0.000 claims 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 abstract description 12
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000013365 dairy product Nutrition 0.000 abstract description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 3
- 230000035764 nutrition Effects 0.000 abstract 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 12
- 235000020778 linoleic acid Nutrition 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 241000186000 Bifidobacterium Species 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 102000036675 Myoglobin Human genes 0.000 description 4
- 108010062374 Myoglobin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 235000021243 milk fat Nutrition 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people, belonging to the field of dairy product processing. The raw materials comprise raw milk dry matter, skim milk powder, desalted whey powder, isomaltitol, dietary fiber, crystalline fructose, vegetable oil, bovine bone collagen peptide, milk mineral salt, phytosterol ester, compound vitamin, compound mineral, yeast beta-glucan, honey powder, phosphatidylserine, selenium-enriched yeast, lactoferrin and probiotic combination. The milk powder can provide more comprehensive and scientific nutrition aiming at the health condition and the nutritional requirements of middle-aged and elderly people, is added with functional components such as isomaltitol, bovine bone collagen peptide, milk mineral salt, phytosterol ester, yeast beta-glucan, lactoferrin, phosphatidylserine, conjugated linoleic acid and the like, and is more suitable for middle-aged and elderly people with diabetes and hypertension and obese people.
Description
Technical Field
The application relates to the field of dairy product processing, in particular to probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people.
Background
In recent years, the health condition of middle-aged and elderly people is more and more concerned, the symptoms of hyperlipidemia, hypertension and hyperglycemia of the middle-aged and elderly people are common, the incidence rate of cardiovascular and cerebrovascular diseases is higher, the current commercially available Chinese aged formula milk powder is a single nutritional supplement, and the nutritional ingredients cannot well meet the nutritional requirements of the middle-aged and elderly people. Therefore, it is very important to design a formula milk powder really suitable for the health condition and nutritional requirements of middle-aged and elderly people, and a formula milk powder suitable for diabetes and hypertension people is urgently needed.
Disclosure of Invention
The application provides a probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people, which aims to solve or partially solve the problems related to the background technology.
The application provides a probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people, which comprises the following components in parts by mass: 20.6-22.6 parts of raw milk dry matter; 29.2-30.8 parts of skim milk powder; 19.2-20.8 parts of desalted whey powder; 10.0-11.0 parts of isomalt; 5.7-6.7 parts of dietary fiber; 4.8-5.2 parts of crystalline fructose; 3.2-3.8 parts of vegetable oil; 0.9-1.1 parts of bovine bone collagen peptide; 0.75-0.85 parts of milk mineral salt; 0.37-0.43 parts of phytosterol ester; 0.245-0.255 parts of compound vitamin; 0.18-0.22 parts of compound mineral; 0.09-0.11 part of yeast beta-glucan; 0.09-0.11 part of honey powder; 0.045-0.055 parts of phosphatidylserine; 0.009-0.011 part of selenium-enriched yeast; 0.009-0.011 part of lactoferrin; 0.009-0.011 part of probiotic combination.
In some embodiments, the dietary fiber comprises the following raw material components in parts by mass: 76.4-77.4 parts of malto-oligosaccharide and 22.6-23.6 parts of inulin.
In some embodiments, the vegetable oil comprises the following raw material components in parts by mass: 93.8-94.8 parts of soybean oil and 5.2-6.2 parts of conjugated linoleic acid. Wherein the conjugated linoleic acid includes, but is not limited to, cis-9, trans-11-conjugated linoleic acid or trans-9, cis-11-conjugated linoleic acid or trans-9, trans-11-conjugated linoleic acid or cis-9, cis-11-conjugated linoleic acid or trans-10, cis-12-conjugated linoleic acid or cis-10, trans-12-conjugated linoleic acid or cis-10, cis-12-conjugated linoleic acid or trans-10, trans-12-conjugated linoleic acid or cis-8, trans-10-conjugated linoleic acid or trans-8, cis-10-conjugated linoleic acid or cis-8, cis-10-conjugated linoleic acid or trans-8, trans-10-conjugated linoleic acid or trans-11, cis-13-conjugated linoleic acid or cis-11, trans-13-conjugated linoleic acid or cis-11, cis-13-conjugated linoleic acid or trans-11, trans-13-conjugated linoleic acid.
In some embodiments, the vitamin formulation comprises vitamin a retinyl acetate, cholecalciferol, dl-alpha-tocopherol acetate, pyridoxine hydrochloride, L-ascorbic acid, taurine, and lactose.
Further, the mass part ratio of each component in the compound vitamin is as follows: 2.660-2.668 parts of vitamin A retinyl acetate; 1.730-1.746 parts of cholecalciferol; 23.50-24.32 parts of dl-alpha-tocopheryl acetate; 0.0575-0.0590 parts of pyridoxine hydrochloride; 36.60-36.84 parts of L-ascorbic acid; 18.00-18.80 parts of taurine; 15.90-16.10 parts of lactose.
In some embodiments, the compound minerals include ferrous sulfate, zinc sulfate, and lactose.
Further, the compound mineral comprises the following components in parts by mass: 24.5-25.5 parts of ferrous sulfate, 7.90-8.90 parts of zinc sulfate and 66.1-67.1 parts of lactose.
In some embodiments, the probiotic combination comprises the following components in parts by mass: bifidobacterium animalis BB-11532.8-33.8 parts, Lactobacillus rhamnosus MP 10832.8-33.8 parts, and Bifidobacterium longum subspecies lactis BLI-0232.8-33.8 parts.
According to the technical scheme of the embodiment, at least one of the following advantages can be obtained.
The formula milk powder is designed by researching the formula milk powder for middle-aged and old people on the market and referring to the national standard of corresponding food safety of China, and is suitable for middle-aged and old people to eat. The formula milk powder can well match the health requirements of middle-aged and elderly people, and also has the effects of health care and conditioning.
The formula milk powder disclosed by the invention reduces the content of milk fat in the formula by reducing the usage amount of raw milk. Through self-checking, the content of trans fatty acid in milk fat is 5.32 percent, the usage amount of raw milk in the formula is about 1800 kg/ton powder, and the fat content of the raw milk is 3.5-4.0 percent; the soybean oil and the conjugated linoleic acid do not contain trans-fatty acid, the proportion of the trans-fatty acid in the formula to the total fatty acid is 3.25-3.72%, and the total content is 0.32-0.37 g/100 g.
Because the human body can not synthesize linoleic acid or the synthesized amount of the essential fatty acid can not meet the requirement, the formula milk powder of the invention increases the content of the linoleic acid by adding soybean oil, the designed content of the linoleic acid in the formula is about 2.52g/100g, wherein the addition amount of the conjugated linoleic acid is about 0.2g/100 g and accounts for 6 percent of the total amount of the linoleic acid. Linoleic acid has effects of reducing blood cholesterol, softening blood vessel, lowering blood pressure, promoting microcirculation, preventing atherosclerosis and senile obesity, and reducing incidence of cardiovascular disease and cerebrovascular disease. The conjugated linoleic acid as one new food material has the functions of linoleic acid as well as other functions, such as raising antioxidant capacity, immunity, cardiac myoglobin content, skeletal myoglobin content, cell membrane flowability, eliminating free radical, resisting cancer, etc.
Because the content of the lactose-degrading enzyme in the middle-aged and the elderly people is low, lactose intolerance is easily caused by excessive intake of lactose, and symptoms such as abdominal distension, abdominal pain and the like appear. The formula milk powder reduces the content of lactose by adjusting the proportion of carbohydrates, and the formula is enhanced with special sweetener crystalline fructose and isomaltitol, wherein the addition proportion of the crystalline fructose is 5.0 percent; the proportion of isomalt added was 10.5%. The crystalline fructose has sweetness 1.8 times of sucrose, and can inhibit excessive storage of human body fat, inhibit dental caries, and promote calcium absorption. The sweetness of the isomaltitol is 45-65% of that of the cane sugar, does not cause decayed teeth, has synergistic effect with the bifidobacteria in the formula, can promote the growth and the reproduction of the bifidobacteria, improve the intestinal function of middle-aged and elderly people and maintain the microecological balance. The isomaltulose alcohol and the crystalline fructose can not cause the increase of blood sugar and insulin in vivo, and are suitable for people with diabetes and obesity.
The formula milk powder of the invention is also added with a special component of bovine bone collagen peptide. The collagen is easy to be absorbed by human body, and has effects of increasing skin elasticity, preventing and treating osteoporosis and cancer, and regulating electrolyte balance in human body.
The formula milk powder selects the milk mineral salt with high absorptivity as the source of calcium, the addition amount of the milk mineral salt in the formula is about 8 kg/ton of powder, and the calcium strengthening amount in the final product is about 200mg/100g of powder. The milk mineral salt is natural active high milk protein calcium, has a scientific calcium-phosphorus ratio of 2:1, is easy to be absorbed and utilized by human bodies, has a greatly higher absorption rate than other common calcium, has little stimulation to intestines and stomach, does not cause discomfort to the intestines and stomach, and is friendly to middle-aged and old people.
The selenium reinforcing source in the formula milk powder selects Angel yeast biology Limited company to produce organic selenium-enriched yeast, and the reinforcing amount of the yeast selenium in the formula is about 20 mug/100 g. The selenium in the selenium-enriched yeast is pure ecological selenium, has high human body absorption rate and no toxic or side effect.
The probiotic combination added in the formula milk powder disclosed by the invention is animal bifidobacterium BB-115, lactobacillus rhamnosus MP108 and bifidobacterium longum subspecies of infant BLI-02, and can inhibit pathogenic bacteria in intestinal tracts and regulate intestinal tract microecology.
The phytosterol ester added in the formula milk powder can reduce the cholesterol content in blood and prevent cardiovascular and cerebrovascular diseases; the yeast beta-glucan and the lactoferrin can enhance the immunity of the organism and inhibit the growth of tumors; phosphatidylserine can improve brain function, improve attention, and improve memory.
Detailed Description
The following specific embodiments are provided to further illustrate the present invention, but the present invention is not limited to only the following embodiments.
Example 1
The embodiment provides a probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people, which comprises the following components in parts by weight per ton: the raw milk comprises 1800kg of dry matter content 206kg, skim milk powder 292kg, desalted whey powder 192kg, isomalt 100kg, dietary fiber 57kg, crystalline fructose 48kg, vegetable oil 32kg, bovine bone collagen peptide 9kg, milk mineral salt 7.5kg, phytosterol ester 3.7kg, compound vitamin 2.45kg, compound mineral 1.8kg, yeast beta-glucan 0.9kg, honey powder 0.9kg, phosphatidylserine 0.45kg, selenium-enriched yeast 0.09kg, lactoferrin 0.09kg and probiotic combination 0.09 kg.
Further, the dietary fiber comprises 43.55kg of oligomeric maltose and 13.45kg of inulin; the vegetable oil comprises 30.02kg of soybean oil and 1.98kg of conjugated linoleic acid; the compound vitamins comprise 0.0652kg of vitamin A retinyl acetate, 0.0424kg of cholecalciferol, 0.5758kg of dl-alpha-tocopherol acetate, 0.0141kg of pyridoxine hydrochloride, 0.8967kg of L-ascorbic acid, 0.4606kg of taurine and 0.3945kg of lactose; the compound mineral comprises 0.450kg of ferrous sulfate, 0.160kg of zinc sulfate and 1.190kg of lactose; the probiotic composition comprises animal Bifidobacterium BB-1150.02952 kg, Lactobacillus rhamnosus MP1080.02997kg, and Bifidobacterium longum subspecies infantis BLI-020.03042 kg.
Further, conjugated linoleic acid includes, but is not limited to, cis-9, trans-11-conjugated linoleic acid or trans-9, cis-11-conjugated linoleic acid or trans-9, trans-11-conjugated linoleic acid or cis-9, cis-11-conjugated linoleic acid or trans-10, cis-12-conjugated linoleic acid or cis-10, trans-12-conjugated linoleic acid or cis-10, cis-12-conjugated linoleic acid or trans-10, trans-12-conjugated linoleic acid or cis-8, trans-10-conjugated linoleic acid or trans-8, cis-10-conjugated linoleic acid or cis-8, cis-10-conjugated linoleic acid or trans-8, trans-10-conjugated linoleic acid or trans-11, cis-13-conjugated linoleic acid or cis-11, trans-13-conjugated linoleic acid or cis-11, cis-13-conjugated linoleic acid or trans-11, trans-13-conjugated linoleic acid.
Example 2
The embodiment provides a probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people, which comprises the following components in parts by weight per ton: the milk comprises 1800kg of raw milk, 216kg of dry matter content, 300kg of skim milk powder, 200kg of desalted whey powder, 105kg of isomaltitol, 65kg of dietary fiber, 50kg of crystalline fructose, 35kg of vegetable oil, 10kg of bovine bone collagen peptide, 8kg of milk mineral salt, 4kg of phytosterol ester, 2.5kg of vitamin complex, 2.0kg of complex mineral matter, 1.0kg of yeast beta-glucan, 1.0kg of honey powder, 0.5kg of phosphatidylserine, 0.1kg of selenium-enriched yeast, 0.1kg of lactoferrin and 0.1kg of probiotic combination.
Further, the dietary fiber comprises 49.98kg of oligomeric maltose and 15.02kg of inulin; the vegetable oil comprises 33.0kg of soybean oil and 2.0kg of conjugated linoleic acid; the compound vitamins comprise 0.0667kg of vitamin A retinyl acetate, 0.0437kg of cholecalciferol, 0.6080kg of dl-alpha-tocopherol acetate, 0.0147kg of pyridoxine hydrochloride, 0.9210kg of L-ascorbic acid, 0.4500kg of taurine and 0.3975kg of lactose; the compound mineral comprises 0.490kg ferrous sulfate, 0.168kg zinc sulfate and 1.342kg lactose; the probiotic composition comprises animal Bifidobacterium BB-1150.0338 kg, Lactobacillus rhamnosus MP1080.0328kg, and Bifidobacterium longum subspecies of infant BLI-020.0333 kg.
Further, conjugated linoleic acid includes, but is not limited to, cis-9, trans-11-conjugated linoleic acid or trans-9, cis-11-conjugated linoleic acid or trans-9, trans-11-conjugated linoleic acid or cis-9, cis-11-conjugated linoleic acid or trans-10, cis-12-conjugated linoleic acid or cis-10, trans-12-conjugated linoleic acid or cis-10, cis-12-conjugated linoleic acid or trans-10, trans-12-conjugated linoleic acid or cis-8, trans-10-conjugated linoleic acid or trans-8, cis-10-conjugated linoleic acid or cis-8, cis-10-conjugated linoleic acid or trans-8, trans-10-conjugated linoleic acid or trans-11, cis-13-conjugated linoleic acid or cis-11, trans-13-conjugated linoleic acid or cis-11, cis-13-conjugated linoleic acid or trans-11, trans-13-conjugated linoleic acid.
Example 3
The embodiment provides a probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people, which comprises the following components in parts by weight per ton: the milk comprises 1800kg of raw milk, 226kg of dry matter content, 308kg of skim milk powder, 208kg of desalted whey powder, 110kg of isomaltitol, 67kg of dietary fiber, 52kg of crystalline fructose, 38kg of vegetable oil, 11kg of bovine bone collagen peptide, 8.5kg of milk mineral salt, 4.3kg of phytosterol ester, 2.55kg of vitamin complex, 2.2kg of complex mineral, 1.1kg of yeast beta-glucan, 1.1kg of honey powder, 0.55kg of phosphatidylserine, 0.11kg of selenium-enriched yeast, 0.11kg of lactoferrin and 0.11kg of probiotic combination.
Further, the dietary fiber comprises 50kg of malto-oligosaccharide and 15kg of inulin; the vegetable oil comprises 33.0kg of soybean oil and 2.0kg of conjugated linoleic acid; the compound vitamins comprise 0.0679kg of vitamin A retinyl acetate, 0.0443kg of cholecalciferol, 0.6097kg of dl-alpha-tocopherol acetate, 0.0149kg of pyridoxine hydrochloride, 0.9364kg of L-ascorbic acid, 0.4692kg of taurine and 0.4080kg of lactose; the compound mineral comprises 0.561kg of ferrous sulfate, 0.174kg of zinc sulfate and 1.465kg of lactose; the probiotic composition comprises animal Bifidobacterium BB-1150.03663 kg, Lactobacillus rhamnosus MP1080.03718kg, and Bifidobacterium longum subspecies of infant BLI-020.03608 kg.
Further, conjugated linoleic acid includes, but is not limited to, cis-9, trans-11-conjugated linoleic acid or trans-9, cis-11-conjugated linoleic acid or trans-9, trans-11-conjugated linoleic acid or cis-9, cis-11-conjugated linoleic acid or trans-10, cis-12-conjugated linoleic acid or cis-10, trans-12-conjugated linoleic acid or cis-10, cis-12-conjugated linoleic acid or trans-10, trans-12-conjugated linoleic acid or cis-8, trans-10-conjugated linoleic acid or trans-8, cis-10-conjugated linoleic acid or cis-8, cis-10-conjugated linoleic acid or trans-8, trans-10-conjugated linoleic acid or trans-11, cis-13-conjugated linoleic acid or cis-11, trans-13-conjugated linoleic acid or cis-11, cis-13-conjugated linoleic acid or trans-11, trans-13-conjugated linoleic acid.
The formula milk powder disclosed by the invention reduces the content of milk fat in the formula by reducing the usage amount of raw milk. Through self-checking, the content of trans fatty acid in milk fat is 5.32 percent, the usage amount of raw milk in the formula is about 1800 kg/ton powder, and the fat content of the raw milk is 3.5-4.0 percent; the soybean oil and the conjugated linoleic acid do not contain trans-fatty acid, the proportion of the trans-fatty acid in the formula to the total fatty acid is 3.25-3.72%, and the total content is 0.32-0.37 g/100 g.
Because the human body can not synthesize linoleic acid or the synthesized amount of the essential fatty acid can not meet the requirement, the formula milk powder of the invention increases the content of the linoleic acid by adding soybean oil, the designed content of the linoleic acid in the formula is about 2.52g/100g, wherein the addition amount of the conjugated linoleic acid is about 0.2g/100 g and accounts for 6 percent of the total amount of the linoleic acid. Linoleic acid has effects of reducing blood cholesterol, softening blood vessel, lowering blood pressure, promoting microcirculation, preventing atherosclerosis and senile obesity, and reducing incidence of cardiovascular disease and cerebrovascular disease. The conjugated linoleic acid as one new food material has the functions of linoleic acid as well as other functions, such as raising antioxidant capacity, immunity, cardiac myoglobin content, skeletal myoglobin content, cell membrane flowability, eliminating free radical, resisting cancer, etc.
Because the content of the lactose-degrading enzyme in the middle-aged and the elderly people is low, lactose intolerance is easily caused by excessive intake of lactose, and symptoms such as abdominal distension, abdominal pain and the like appear. The formula milk powder reduces the content of lactose by adjusting the proportion of carbohydrates, and the special sweetener crystalline fructose and isomaltitol are enhanced in the formula, wherein the addition proportion of the crystalline fructose is about 5.0 percent; the proportion of isomalt added was about 10.5%. The crystalline fructose has sweetness 1.8 times of sucrose, and can inhibit excessive storage of human body fat, inhibit dental caries, and promote calcium absorption. The sweetness of the isomaltitol is 45-65% of that of the cane sugar, does not cause decayed teeth, has synergistic effect with the bifidobacteria in the formula, can promote the growth and the reproduction of the bifidobacteria, improve the intestinal function of middle-aged and elderly people and maintain the microecological balance. The isomaltulose alcohol and the crystalline fructose can not cause the increase of blood sugar and insulin in vivo, and are suitable for people with diabetes and obesity.
The formula milk powder of the invention is also added with a special component of bovine bone collagen peptide. The collagen is easy to be absorbed by human body, and has effects of increasing skin elasticity, preventing and treating osteoporosis and cancer, and regulating electrolyte balance in human body.
The formula milk powder selects the milk mineral salt with high absorptivity as the source of calcium, the addition amount of the milk mineral salt in the formula is about 8 kg/ton of powder, and the calcium strengthening amount in the final product is about 200mg/100g of powder. The milk mineral salt is natural active high milk protein calcium, has a scientific calcium-phosphorus ratio of 2:1, is easy to be absorbed and utilized by human bodies, has a greatly higher absorption rate than other common calcium, has little stimulation to intestines and stomach, does not cause discomfort to the intestines and stomach, and is friendly to middle-aged and old people.
The selenium reinforcing source in the formula milk powder selects Angel yeast biology Limited company to produce organic selenium-enriched yeast, and the reinforcing amount of the yeast selenium in the formula is about 20 mug/100 g. The selenium in the selenium-enriched yeast is pure ecological selenium, has high human body absorption rate and no toxic or side effect.
The probiotic combination added in the formula milk powder disclosed by the invention is animal bifidobacterium BB-115, lactobacillus rhamnosus MP108 and bifidobacterium longum subspecies of infant BLI-02, and can inhibit pathogenic bacteria in intestinal tracts and regulate intestinal tract microecology.
The phytosterol ester added in the formula milk powder can reduce the cholesterol content in blood and prevent cardiovascular and cerebrovascular diseases; the yeast beta-glucan and the lactoferrin can enhance the immunity of the organism and inhibit the growth of tumors; phosphatidylserine can improve brain function, improve attention, and improve memory.
According to the selenium-rich high-calcium probiotic formula milk powder for middle-aged and elderly people, comprehensive and really suitable nutrient substances for health conditions and nutritional requirements of middle-aged and elderly people are added, so that the health requirements of the middle-aged and elderly people can be well matched, and the effects of health care and conditioning can be further achieved.
Claims (10)
1. The probiotic selenium-rich high-calcium formula milk powder for the middle-aged and the elderly is characterized by comprising the following components in parts by mass: 20.6-22.6 parts of raw milk dry matter; 29.2-30.8 parts of skim milk powder; 19.2-20.8 parts of desalted whey powder; 10.0-11.0 parts of isomalt; 5.7-6.7 parts of dietary fiber; 4.8-5.2 parts of crystalline fructose; 3.2-3.8 parts of vegetable oil; 0.9-1.1 parts of bovine bone collagen peptide; 0.75-0.85 parts of milk mineral salt; 0.37-0.43 parts of phytosterol ester; 0.245-0.255 parts of compound vitamin; 0.18-0.22 parts of compound mineral; 0.09-0.11 part of yeast beta-glucan; 0.09-0.11 part of honey powder; 0.045-0.055 parts of phosphatidylserine; 0.009-0.011 part of selenium-enriched yeast; 0.009-0.011 part of lactoferrin; 0.009-0.011 part of probiotic combination.
2. The probiotic selenium-enriched high-calcium mid-aged formula according to claim 1, wherein the dietary fiber comprises malto-oligosaccharide and inulin.
3. The probiotic selenium-rich high-calcium middle-aged and elderly formula milk powder according to claim 2, wherein the dietary fiber comprises the following components in parts by weight: 76.4-77.4 parts of malto-oligosaccharide and 22.6-23.6 parts of inulin.
4. The probiotic selenium-enriched high-calcium mid-aged formula milk powder according to claim 1, wherein the vegetable oil comprises soybean oil and conjugated linoleic acid.
5. The probiotic selenium-rich high-calcium middle-aged and elderly formula milk powder according to claim 4, wherein the vegetable oil comprises the following components in parts by weight: 93.8 to 94.8 parts of soybean oil, 5.2 to 6.2 parts of conjugated linoleic acid,
wherein the conjugated linoleic acid comprises cis-9, trans-11-conjugated linoleic acid or trans-9, cis-11-conjugated linoleic acid or trans-9, trans-11-conjugated linoleic acid or cis-9, cis-11-conjugated linoleic acid or trans-10, cis-12-conjugated linoleic acid or cis-10, trans-12-conjugated linoleic acid or cis-10, cis-12-conjugated linoleic acid or trans-10, trans-12-conjugated linoleic acid or cis-8, trans-10-conjugated linoleic acid or trans-8, cis-10-conjugated linoleic acid or cis-8, cis-10-conjugated linoleic acid or trans-8, trans-10-conjugated linoleic acid or trans-11, at least one of cis-13-conjugated linoleic acid or cis-11, trans-13-conjugated linoleic acid or cis-11, cis-13-conjugated linoleic acid or trans-11, trans-13-conjugated linoleic acid.
6. The probiotic selenium-enriched high-calcium mid-aged formula according to claim 1, wherein the multivitamins comprise vitamin a retinyl acetate, cholecalciferol, dl-alpha-tocopherol acetate, pyridoxine hydrochloride, L-ascorbic acid, taurine and lactose.
7. The probiotic selenium-rich high-calcium middle-aged and elderly formula milk powder according to claim 6, wherein the compound vitamin comprises the following components in parts by weight: 2.660-2.668 parts of vitamin A retinyl acetate; 1.730-1.746 parts of cholecalciferol; 23.50-24.32 parts of dl-alpha-tocopheryl acetate; 0.0575-0.0590 parts of pyridoxine hydrochloride; 36.60-36.84 parts of L-ascorbic acid; 18.00-18.80 parts of taurine; 15.90-16.10 parts of lactose.
8. The probiotic selenium-enriched high-calcium middle-aged and elderly formula milk powder of claim 1, wherein the compound minerals comprise ferrous sulfate, zinc sulfate and lactose.
9. The probiotic selenium-rich high-calcium middle-aged and elderly formula milk powder according to claim 8, wherein the compound mineral comprises the following components in parts by weight: 24.5-25.5 parts of ferrous sulfate, 7.90-8.90 parts of zinc sulfate and 66.1-67.1 parts of lactose.
10. The probiotic selenium-rich high-calcium middle-aged and elderly formula milk powder according to claim 1, wherein the probiotic composition comprises the following components in parts by mass: bifidobacterium animalis BB-11532.8-33.8 parts, Lactobacillus rhamnosus MP 10832.8-33.8 parts, and Bifidobacterium longum subspecies lactis BLI-0232.8-33.8 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110954228.4A CN113693131A (en) | 2021-08-19 | 2021-08-19 | Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110954228.4A CN113693131A (en) | 2021-08-19 | 2021-08-19 | Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113693131A true CN113693131A (en) | 2021-11-26 |
Family
ID=78653449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110954228.4A Pending CN113693131A (en) | 2021-08-19 | 2021-08-19 | Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113693131A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023104181A1 (en) * | 2021-12-10 | 2023-06-15 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
| WO2023237680A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
| WO2023237673A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
| WO2023237677A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
| WO2023237681A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111602720A (en) * | 2020-05-11 | 2020-09-01 | 呼伦贝尔双娃乳业有限公司 | Formula milk powder for middle-aged and old people |
-
2021
- 2021-08-19 CN CN202110954228.4A patent/CN113693131A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111602720A (en) * | 2020-05-11 | 2020-09-01 | 呼伦贝尔双娃乳业有限公司 | Formula milk powder for middle-aged and old people |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023104181A1 (en) * | 2021-12-10 | 2023-06-15 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
| WO2023237680A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
| WO2023237673A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
| WO2023237677A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
| WO2023237681A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113693131A (en) | Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people | |
| CN101248900B (en) | Novel solid sport drink medicinal granules | |
| CN102511720B (en) | Stachyose infant nourishing cereal and its preparation method | |
| CN109198356A (en) | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal | |
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN111602720A (en) | Formula milk powder for middle-aged and old people | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN108272078A (en) | Special medicine purposes formula food meal replacement powder of control body weight and preparation method thereof | |
| CN102273585A (en) | Health-care porridge with effect of relaxing bowel and preparation method thereof | |
| CN111771971A (en) | Composition beneficial to regulating intestinal tract, promoting digestion and improving constipation and preparation method thereof | |
| CN111802550A (en) | Probiotic formula beverage and preparation method thereof | |
| CN103371318B (en) | Dietary nutrition replenishing food | |
| CN104738638A (en) | Composition with anti-fatigue effect and application thereof | |
| CN105076425A (en) | Yak, cow and ewe three-in-one composite infant formula milk powder | |
| CN107889997A (en) | A kind of Freeze-dry Powder of Probioctics solid beverage | |
| CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
| CN107467193B (en) | A powder food based on goat milk for special medical use and its preparation method | |
| CN113598231A (en) | Sucrose-free yogurt added with composite dietary fiber and humanized probiotics and preparation method thereof | |
| CN102273581A (en) | Compound sweetener with high sweetness | |
| CN105358127A (en) | Petroselinic acid or a combination of active ingredients comprising at least petroselinic acid for promoting weight loss and/or weight maintenance | |
| CN109303115A (en) | Raw ketone weight losing meal-replacing milk shake | |
| CN115590204A (en) | Composition for enhancing anti-aging of mammals | |
| CN110959797A (en) | Prebiotics soybean protein peptide solid beverage and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |